AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

Conditions: Aortic Stenosis

Sex: All

Ages: 65 Years – 80 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 360

Sponsor: Oslo University Hospital

Location: Oslo Univesity Hospital - Ullevål Oslo Oslo

Summary

ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation therapy versus the standard antiplatelet therapy after transcatheter aortic valve implantation in patients with aortic stenosis. The trial will assess the efficacy of direct oral anticoagulation (DOAC) therapy compared to the standard single antiplatelet therapy to prevent degeneration of the valve and its safety in co-primary endpoints with blinded endpoint adjudication. The effect of DOAC therapy on hard clinical outcomes will be assessed during long-term follow-up.

Eligibility Criteria

Inclusion Criteria: * Successful trans-catheter aortic valve implantation in patients aged \>65 and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05035277). StuddyBuddy aggregates publicly available trial information.